

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

May 13, 2019  
Date of Report (Date of Earliest Event Reported)



**The Chemours Company**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
Of Incorporation)

**001-36794**  
(Commission  
File Number)

**46-4845564**  
(I.R.S. Employer  
Identification No.)

**1007 Market Street**  
**Wilmington, Delaware, 19899**  
(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

**Title of Each Class**  
Common Stock (\$.01 par value)

**Trading Symbol(s)**  
CC

**Name of Exchange on Which Registered**  
New York Stock Exchange

**Item 7.01. Regulation FD Disclosure.**

On May 13, 2019, The Chemours Company (the “Company”) posted a presentation to the Investor Relations section of the Company’s website which will be used for upcoming discussions with investors. The presentation is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

**Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans, prospects, targets, goals and commitments, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for net sales, Adjusted EBITDA, Adjusted EPS, Free Cash Flow, Adjusted Effective Tax Rate, and Return on Invested Capital, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond the Company’s control. Additionally, there may be other risks and uncertainties that the Company is unable to identify at this time or that the Company does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2018. The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 [Investor Presentation.](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

By: /s/ Mark E. Newman  
Mark E. Newman  
Senior Vice President and  
Chief Financial Officer

Date: May 13, 2019



# The Chemours Company

**Investor Presentation**  
*May 13, 2019*



# Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future performance and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak to future performance. These forward-looking statements may address, among other things, the outcome or resolution of any litigation, commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or resolution of any environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, performance, business plans, prospects, targets, goals and commitments, capital investments and projects, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings. Key financial measures include EBITDA, Adjusted Net Income, Adjusted EPS, Free Cash Flow, Adjusted Effective Tax Rate, and Return on Investment. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or reflect actual future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our SEC filings and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, and we may update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). We also present Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Effective Tax Rate, and Adjusted Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because they provide greater transparency with respect to supplemental information used by management in making business decisions. Further information with respect to and reconciliations of such measures to the nearest GAAP measure is available in our SEC filings.

Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Effective Tax Rate, and Adjusted Net Leverage Ratio to evaluate the company's performance excluding the impact of certain noncash charges and items that are infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business.

Additional information for investors is available on the company's website at [investors.chemours.com](http://investors.chemours.com).



# Chemours Investment Thesis

**Leveraging**

industry-leading positions to drive top-line growth

**Investing**

in our core businesses with high ROIC (+30%) providing a competitive advantage

**Strengthening**

our existing businesses through targeted M&A

**Returning**

the majority of our Free Cash Flow to shareholders through a growing dividend and meaningful share repurchases

**Harnessing**

the energy of the organization, generated through our agile structure to move at high velocity



Chemours™

# The Chemours Company at a Glance

(\$ in millions)

## Total Chemours

### Net Sales

\$6,284




TTM 1Q19

### Adjusted EBITDA

◇ Adjusted EBITDA Margin

\$1,535



TTM 1Q19

## Fluoroproducts

### Net Sales

\$2,819




TTM 1Q19

### Adjusted EBITDA

◇ Adjusted EBITDA Margin

\$735



TTM 1Q19

## Chemical Solutions

### Net Sales

\$591



TTM 1Q19

### Adjusted EBITDA


◇ Adjusted EBITDA Margin

\$69




TTM 1Q19

## Adjusted EBITDA Growth



## Product<sup>1</sup>



1. Data represents net sales

See reconciliation of Non-GAAP measures in the appendix

# Fluoroproducts Business Summary

## BUSINESS OVERVIEW

- Global market leader in Fluoroproducts
- Supplies fluoropolymer products for high performance applications across broad array of industries
- Supplies fluorochemical products for air conditioning, refrigeration and foam blowing agent markets
- Brands: Teflon™, Freon™, Opteon™, Krytox™, Nafion™, Viton™



## FINANCIAL

\$ Millions

Revenue

Adjusted EBITD

Adj. EBITDA  
Margin



**Fluoropolymer**  
products and c

**Fluorochemical**  
foam blowing a

**Key end market**  
refrigeration, a  
communication  
oil & gas, aéro






1. Segment net sales

See reconciliation of Non-GAAP measures in the appendix



# Fluorochemicals Long-Term Market View

	2016	REVENUE
<b>MOBILE</b> 	<b>\$1B</b> ~\$450M ~\$550M	<b>12% CAGR</b> <b>(1%) CAGR</b>
<b>STATIONARY</b> 	<b>\$3.7B</b> ~\$50M ~\$3.65B	<b>42% CAGR</b> <b>3% CAGR</b>
<b>FOAM BLOWING AGENTS</b> 	<b>\$0.7B</b> ~\$50M ~\$650M	<b>31% CAGR</b> <b>(11%) CAGR</b>

Chemours Is Well Positioned to Capture Market Growth and Value for



Source: Industry trade publications, com

# Stationary Market Breakdown

## COMMERCIAL REFRIGERATION



\$1.1B

2016

~\$0.05B

~\$1.05B

REVENUE

35% CAGR

(8%) CAGR

## AIR CONDITIONING



\$2.3B

~\$0.0B

~\$2.3B

133% CAGR

6% CAGR

## CHILLERS



\$0.3B

~\$0.0B

~\$0.3B

88% CAGR


5% CAGR

Attractive Growth in Stationary Markets Expected



Source: Industry trade publi  
Note: CAGRs are based up

# Opteon™ Advantage - CO<sub>2</sub> Equivalent Basis



Opteon™ Offers Low GWP Alternatives that Meet Tightening

# Opteon™ Patent Estate

- Our multinational portfolio includes nearly 900 patents and pending applications on HFO technology, including compositions, uses and processes of manufacture
- The earliest patents on HFO technology are expected to expire in the mid-2020's
  - We continue to add to our patent application estate
- Chemours actively monitors for patent infringement and will vigorously assert its rights under these patents, including seeking damages and injunctions to stop infringement

2023

2026

2030s

The Size and Scope of Our Portfolio Means Loss of Any One Single Patent Will Not Significantly Affect O



# Fluoropolymers Target Markets for Application

	2016 Market Size*	2016 - 2027 CAGR	2027 Market Size*	Ti
--	----------------------	---------------------	----------------------	----

**Automotive**



\$1,100

5%

\$1,900

•  
•  
•

**Renewable  
Energy &  
Storage**




\$105

21%

\$850

•  
•

**Consumer  
Electronics &  
Communications**



\$910

9%

\$2,300

•  
•



Sources: McKinsey; Bain; IHS BCC, US Department of Energy, Chemours sales data and  
\* \$ Millions; Addressable market size based on current applications, ingredients

# Recent Wins and Our Application Development



DATA CENTERS

ENERGY STORAGE




USB-C CABLES

HYBRID VEHICLES



MOBILE DEVICE ANTENNAS

- Energy
- Automotive
- Consumer Electronics & Communication



Strong Pipeline Build Since Announcing Application Development



# Chemical Solutions Business Overview

## BUSINESS OVERVIEW

- Portfolio of industrial businesses primarily operating in the Americas
- Reputation for safety, reliability and stewardship
- Three production facilities located in North America
  - Memphis, TN: Mining Solutions
  - Belle, WV: PC&I
  - Pascagoula, MS: PC&I



## FINANCIAL

\$ Millions

Revenue

Adjusted EBITDA

Adj. EBITDA Margin



**Mining Solutions**  
cyanide

**Performance Chemicals & Intermediates**  
methylamines, aniline, nitrobenzene



1. Segment net sales

See reconciliation of Non-GAAP measures in the appendix

# Titanium Technologies Business Overview

## BUSINESS OVERVIEW

- A global leader<sup>1</sup> in TiO<sub>2</sub> with production capacity of 1.25 million metric tons
  - 4 TiO<sub>2</sub> plants with 7 production lines
  - Packaging facility at Kallo, Belgium
  - Mineral sands mine at Starke, FL
- Strong brand reputation
  - Ti-Pure™ sold to approximately 600 customers globally
- Industry-leading manufacturing cost position
  - Unique chloride technology
  - Feedstock flexibility



## FINANCIAL

**\$ Millions**

Revenue

Adjusted EBITDA

Adj. EBITDA  
Margin



**Coatings** – ar

**Plastics** – rigi  
pipe/windows

**Papers** – lami  
paper/paperbo

1. TiO<sub>2</sub> mark

2. Segment net sales for the trailing two

3. Segment net sales for the trailing t



See reconciliation of Non-GAAP measures in the appendix



# Ti-Pure™ Value Stabilization

## CHEMOURS' VISION

- We absorb the demand variance in our customers' marketplace, while holding value-based pricing for Ti-Pure™ products
- Reduced business volatility stabilizes Chemours' cash generation and enables more consistent capacity planning to serve our customers
- We can support and grow our investment in new offerings over time, enhancing growth option for our customers
- **Our customers can focus their efforts on market growth and avoid the distracting seesaw of “can I get the TiO<sub>2</sub> I need?” or “how high will the price go?”**

Manufacturing  
& Supply  
Assurance

## CHEMOURS' APPROACH

- Create contractual relationships with stable customer-Chemours
- Improve our manufacturing operations to economically respond to demand in our customers' sales for Ti-Pure™ TiO<sub>2</sub>
- Deliver value from a sales-based perspective through insights and new offerings

Ti-Pure™ Value Stabilization is Expected to Reduce Volatility and Provide More Predictability for our Customers




# Ti-Pure™ Value Stabilization is a Win-Win

## Value to Customers



- Predictable pricing enables improved supply chain planning
- Reduces need to build and hold excess inventory
- Provides volume certainty over time



- Provide
- Enhance capacity for customer
- Allow for offering customer

# Corporate Responsibility Commitment



## Evolved Portfolio

Sustainable Offerings  
Sustainable Supply Chain



## Inspired People

Safety Excellence  
Vibrant Communities  
Empowered Employees

We will measure, monitor, and report against these o



# Clarifying Fluorine Chemistry

**PFAS** is a broad term encompassing a number of substances produced for a variety of industrial substances, which have been the subject of study and frequent media and public discussion.

- **PFOS and PFOA** are the subject of Drinking Water Health Advisories issued by the EPA
- **PFOS:** Neither Chemours nor DuPont has made or sold PFOS as a commercial product
- **PFOA:**
  - Chemours understands that DuPont made PFOA, from 2002-2013, for use at its own facilities
  - Chemours understands that DuPont did not manufacture PFOA as a commercial product
  - Chemours has never made or sold PFOA as a commercial product, or used PFOA as a processing aid
- **GenX:** A processing aid used in the manufacture of some fluoropolymers where PFOA was used and recycled at Chemours' Fayetteville, North Carolina site pursuant to Consent Order for the manufacture of fluoropolymers. Studies have shown that GenX is not biopersistent in the body



# Our Proactive Approach

## Ongoing Work

### Fayetteville

- Chemours negotiated a Consent Order which was approved by the court in February 2019
- Under the Consent Order, Chemours continues to capture process water
- >\$100m capital commitment to reduce GenX and other facility-wide PFAS air emissions by 99% by end of 2019
- Treatment to be provided for numerous offsite water users

### Washington Works and Chambers Works

- Offsite treatment at Chemours Washington Works, West Virginia and Chambers Works, New Jersey manufacturing sites have been in place for many years

## CRC Commitments

- Reduce air and water organic chemicals by !
- Our 2030 Corporate R built upon three pillar each with their own 2 communities, empower sustainable offerings,

M

- Chemours supports s
- **Chemours will continue to address issues in the**



Chemours™



# The Chemours Company

## Reconciliations



# Segment Net Sales and Adjusted EBITDA (Unaudited)

(\$ in millions)

	Twelve Months Ended Mar	
	2019	2018
<b>SEGMENT NET SALES</b>		
Fluoroproducts	\$ 2,819	\$ 2,819
Chemical Solutions	591	591
Titanium Technologies	2,874	2,874
Total Company	<u>\$ 6,284</u>	<u>\$ 6,284</u>
<b>SEGMENT ADJUSTED EBITDA</b>		
Fluoroproducts	\$ 735	\$ 735
Chemical Solutions	69	69
Titanium Technologies	888	888
Corporate and Other	(157)	(157)
Total Company	<u>\$ 1,535</u>	<u>\$ 1,535</u>
<b>SEGMENT ADJUSTED EBITDA MARGIN</b>		
Fluoroproducts	26.1%	26.1%
Chemical Solutions	11.7%	11.7%
Titanium Technologies	30.9%	30.9%
Corporate and Other	0.0%	0.0%
Total Company	<u>24.4%</u>	<u>24.4%</u>



# Adjusted EBITDA to GAAP Income (Loss) Before Incom (Unaudited)

(\$ in millions)

	2018	2017
<b>Income (loss) before income taxes</b>	<b>\$ 1,155</b>	<b>\$</b>
Interest expense, net	195	
Depreciation and amortization	284	
Non-operating pension and other post-retirement employee benefit income	(27)	
Exchange (gains) losses, net	(1)	
Restructuring, asset-related, and other charges	49	
Loss (gain) on extinguishment of debt	38	
(Gain) loss on sales of assets and businesses	(45)	
Transaction costs	9	
Legal charges	82	
Other charges	1	
<b>Adjusted EBITDA</b>	<b>\$ 1,740</b>	<b>\$</b>





# Adjusted EBITDA to GAAP Income (Loss) Before Incom (Unaudited)

(\$ in millions)

## Income (loss) before income taxes

Interest expense, net

Depreciation and amortization

Non-operating pension and other post-retirement employee benefit income

Exchange (gains) losses, net

Restructuring, asset-related, and other charges

Loss (gain) on extinguishment of debt

(Gain) loss on sales of assets and businesses

Transaction costs

Legal charges

Other charges

**Adjusted EBITDA**

—  
—  
\$

—  
—  
\$



Chemours™

# The Chemours Company



©2018 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company

---

